United States - English - NLM (National Library of Medicine)

genentech, inc. - pertuzumab (unii: k16aiq8ctm) (pertuzumab - unii:k16aiq8ctm), trastuzumab (unii: p188anx8ck) (trastuzumab - unii:p188anx8ck), hyaluronidase (human recombinant) (unii: 743quy4vd8) (hyaluronidase (human recombinant) - unii:743quy4vd8) - phesgo is indicated for use in combination with chemotherapy for - the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see dosage and administration (2.2) and clinical studies (14.2)] . - the adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrence [see dosage and administration (2.2) and clinical studies (14.2)] . select patients for therapy based on an fda-approved companion diagnostic test [see dosage and administration (2.1)]. phesgo is indicated for use in combination with docetaxel for the treatment of adult patients with her2-positive metastatic breast cancer who have not received prior anti-her2 therapy or chemotherapy for metastatic disease [see dosage and administration (2.2) and clinical studies (14.1)] . select patients for therapy based on an fda-approved compa

Canada - English - Health Canada

hoffmann-la roche limited - pertuzumab - solution - 420mg - pertuzumab 420mg - antineoplastic agents

Canada - English - Health Canada

hoffmann-la roche limited - pertuzumab; trastuzumab - solution - 420mg; 440mg - pertuzumab 420mg; trastuzumab 440mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - pertuzumab, quantity: 600 mg; trastuzumab, quantity: 600 mg; water for injections, quantity: 10 ml - injection, solution - excipient ingredients: polysorbate 20; sucrose; histidine; trehalose dihydrate; vorhyaluronidase alfa; histidine hydrochloride monohydrate; methionine - early breast cancer (ebc),phesgo is indicated in combination with chemotherapy for the:,? neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer,? adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence,select patients for therapy based on a validated test.,metastatic breast cancer (mbc),phesgo is indicated in combination with docetaxel for patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease. select patients for therapy based on a validated test.

Kenya - English - Pharmacy and Poisons Board

f. hoffman-la roche ltd, basel grenzacherstrasse 124 ch-4070 basel, switzerland - pertuzumab - concentrate for solution for infusion - one 14 ml vial of concentrate contains 420 mg of… - pertuzumab

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - elotuzumab - powder for solution for infusion - 400mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - elotuzumab - powder for solution for infusion - 300mg

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - pertuzumab; trastuzumab - solution for injection - trastuzumab 40 mg/ml; pertuzumab 80 mg/ml - pertuzumab and trastuzumab - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy for:•the neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer .•the adjuvant treatment of patients with her2-positive early breast cancer (node positive) at high risk of recurrence.metastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel for the treatment of patients with her2-positive metastatic breast cancer who have not received prior anti-her2 therapy or chemotherapy for metastatic disease.

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - pertuzumab; trastuzumab - solution for injection - trastuzumab 60 mg/ml; pertuzumab 60 mg/ml - pertuzumab and trastuzumab - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy for:•the neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer .•the adjuvant treatment of patients with her2-positive early breast cancer (node positive) at high risk of recurrence.metastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel for the treatment of patients with her2-positive metastatic breast cancer who have not received prior anti-her2 therapy or chemotherapy for metastatic disease.

Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - pertuzumab - infusion, solution concentrate - 30 mg/ml - pertuzumab 30 mg/ml